

Special Issue

Human Fungal Pathogens and Emerging Antifungal Resistance—A Global Public Health Problem?

Message from the Guest Editor

Improvements in oncology and transplant medicine has led to increased patient populations with high susceptibility to severe fungal infections. These mostly opportunistic infections are a deadly threat to immunosuppressed patients. In addition, the worldwide growing number of diabetic patients display another patient cohort at risk. Progress in diagnosis has enabled faster species identification of fungal pathogens. Nevertheless, too late diagnosis, fast progression of disease, limited antifungal regimens, changes in epidemiology, and the increasing appearance of resistance result in unacceptably high mortality rates. To fight, or even prevent, severe fungal infections, it is necessary to further advance our understanding of virulence traits and their molecular mechanisms of action in order to identify targets for antifungal drug development. This Special Issue is open to researchers in any related field willing to contribute significant discoveries, or relevant observations in fungal virulence, antifungal resistance mechanisms or identification of putative drug targets.

Guest Editor

Dr. Ulrike Binder

Institute of Hygiene and Medical Microbiology, Medical University Innsbruck, Schöpfstrasse 41, 6020 Innsbruck, Austria

Deadline for manuscript submissions

closed (1 April 2021)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/37721

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))